Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04307329
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Netherlands
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 178
- Registration Number
- NCT04296162
- Locations
- 🇨🇳
Zhi-Ming Shao, Shanghai, China
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04281576
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT04262804
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 15
- Registration Number
- NCT04253561
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain
🇪🇸Hospital Universitario del Vall d' Hebron, Barcelona, Spain
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04236310
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Conditions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT04220203
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04208178
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of California LA, Los Angeles, California, United States
🇪🇸Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1560
- Registration Number
- NCT04193059
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT04188548
- Locations
- 🇺🇸
Winship Cancer Center Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.